跳至主要内容
临床试验/NCT00062660
NCT00062660Approved For Marketing不适用

An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options

Boehringer Ingelheim146 个研究点 分布在 2 个国家开始时间: 2003年5月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
Approved For Marketing
试验地点
146

研究概览

简要总结

To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.

研究设计

研究类型
Expanded Access

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (146)

Loading locations...

相似试验